PATENT CLAIM ANALYSIS

Application Number: 15771914
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-11
Patent Classification: ["514", "253100"]

Abstract:
Disclosed is a mast cell inhibitor, a pharmaceutical composition and a method for the treatment of patients afflicted with Parkinson's disease, wherein the patients are treated with a tyrosine kinase inhibitor or mast cell inhibitor, in particular masitinib, or a compound selected from imatinib, cromolyn sodium, midostaurin, BLU-285, bosutinib, ibrutinib, LAS189386, DP-2618, fostamatinib, dasatinib, sunitinib, axitinib, pazopanib, and toceranib or a pharmaceutically acceptable salt or solvate thereof, optionally in combination with at least one pharmaceutically active ingredient.

Claim (Index 25):
The method according to  claim 20 , wherein said masitinib, or a pharmaceutically acceptable salt or solvate thereof, is administered at an initial dose of 3.0 mg/kg/day (mg per kilo body weight per day) during at least 4 weeks, then 4.5 mg/kg/day during at least 4 weeks, and at 6 mg/kg/day thereafter, with each dose escalation being subjected to toxicity controls.

Metadata:
- Claim Count in Document: 5.0
- Percentile: 91.0
- Lexical Diversity: 1.59016
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15545800', '14957201', '13640857', '13983626', '14433198']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.794575452828492
- 35 USC 102 Novelty (BERT): 0.5321393763902276
- Combined Prediction Score: 0.7683318451846655
- Mean Citation Score: 312.0495279999999
- Max Citation Score: 361.68576
- Similarity Product: 324.8771569825745

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test